Preoperative irradiation and cystectomy in 135 cases of bladder cancer

Reid, Everett C.; Oliver, John A.; Fishman, Irving J.

doi:10.1016/0090-4295(76)90377-0

Cited by 63 publications

(6 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous reports (Whitmore and Marshall, 1962;Dretler e? al., 1973;Laplante and Brice, 1973;Reid et al, 1976;Smith and Whitmore, 1981;Skinner, 1982) have attested to the feasibility of pelvic lymphadenectomy and radical cystectomy, which has provided 5-year survival rates ranging from 7 to 36% (Table 2). On the basis of these reports it seems that the number of nodes involved is a most important variable in predicting survival.…”

Section: Discussionmentioning

confidence: 99%

Pelvic Lymphadenectomy and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder with Pelvic Nodal Disease

Zincke

Patterson

Utz

et al. 1985

British Journal of Urology

View full text Add to dashboard Cite

Past and present methods of treatment for patients with stage D1 (T1-4 N+ MO) transitional cell cancer of the urinary bladder have proved to be largely ineffective. This report on 57 patients with stage D1 disease confirms this impression and demonstrates that radical operation alone is associated with a 5-year survival rate of only 10%. Survival is related to tumour grade and to the number of pelvic lymph nodes involved; furthermore, complete lymphadenectomy may contribute to improved patient survival. Effective treatment programmes for stage D1 bladder cancer are lacking and efforts should be directed toward developing treatment protocols that combine radical cystectomy and meticulous pelvic node dissection with an effective adjuvant systemic treatment programme.

show abstract

Section: Discussionmentioning

confidence: 99%

Pelvic Lymphadenectomy and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder with Pelvic Nodal Disease

Zincke

Patterson

Utz

et al. 1985

British Journal of Urology

View full text Add to dashboard Cite

show abstract

“…Following a pelvic dose of only 350 rad x 3 prior to interstitial therapy in T3 cases, WerfMessing (1978) reported a reduced incidence of scar recurrence and of distant metastases, with an increased 5-year survival rate, compared with radium implant alone. A dose of 2000 rad in one week prior to cystectomy in T3 cases has given results which are not inferior to those following a preoperative dose of 4000 rad in 4 weeks (Whitmore et al 1977, Reid et al 1976) (Table 4).…”

Section: Prognosis Influenced By Agementioning

confidence: 98%

“…Five-year survival rates of 34-50% have been reported for T3 cases following the combined approach in noncontrolled studies at the Rotterdam Radiotherapy Institute (Werf-Messing 1975), the Memorial Hospital, New York (Whitmore et al 1977) and the Montreal General Hospital (Reid et al 1976) (Table 4).…”

Section: Combined Treatmentmentioning

confidence: 99%

Treatment of Infiltrating Bladder Cancer

Bloom

1979

J R Soc Med

View full text Add to dashboard Cite

In the field of urological oncology there can be no greater therapeutic challenge for the urologist and radiotherapist than a bladder tumour which is found to be infiltrating muscle. The threat to life by such lesions is of varying magnitude, depending upon the precise depth of mural infiltration. In patients with tumour limited to the superficial muscle (stage T2), cure is anticipated, whereas in those cases showing involvement of deep muscle or perivesical fat (stage T3a and T3b), therapeutic failure leading to death within two years is not unexpected.Bladder tumours with muscle involvement are not early enough to be dismissed after one or more sessions of transurethral cystodiathermy, nor so late as to be relegated to palliative procedures. A radical approach is required, although in some cases not necessarily amounting to total cystectomy nor to large volume external beam therapy.T2 tumours Before the megavoltage era, interstitial irradiation was an attractive method of treatment, enabling high doses to be delivered locally in a deep-seated organ without heavily irradiating the normal surrounding tissues. With the advent of megavoltage equipment and with more aggressive methods of endoscopic resection, the indications for interstitial treatment for bladder cancer have diminished. Thus, at the Christie Hospital, Manchester, the proportion of cases treated by radioactive implant has fallen from 41% in 1953in , to 3% in 1969in (Pointon 1973.Interstitial irradiation in the bladder now appears to be used at only a few centres, mainly in Europe. The techniques and materials for this type of treatment have been reviewed elsewhere (Bloom & Wallace 1971).The ideal case for interstitial therapy is one with a solitary tumour of relatively low-grade malignancy whose base does not exceed 4-5 cm in diameter, with early muscle infiltration and with no obvious malignant or premalignant changes in the bladder away from the tumour site. This technique has also been employed for patients with mucosal tumours (T1) which are large, sessile and solid-looking, and especially when biopsy shows poor differentiation and there is doubt regarding the precise depth of infiltration.The principal advantages associated with interstitial irradiation are that a substantial cure rate is obtained with a low operative morbidity and mortality (2-4%); that irradiation is restricted to a portion of the bladder wall, with sparing of the extravesical tissues; and that if cure is not achieved, other methods of treatment are not precluded.

show abstract

“…Since the initial experience at the Memorial Sloan-Kettering Cancer Center with 4,000 rad during 4 weeks, various regimens of preoperative radiotherapy have been used, ranging from 2,000 rad in 4 days to 5,000 rad in 5 weeks. In general, the integrated treatment regimens using preoperative radiotherapy in conjunction with radical cystectomy have recorded 5-year survival rates of 30-50% [10][11][12][13][14]. Evidence for the efficacy of integrated preoperative radiotherapy is based upon the improved survival demonstrated in these patients compared to a group of historical controls treated by an operation or radiotherapy alone.…”

Section: Introductionmentioning

confidence: 99%

Treatment alternatives for invasive bladder cancer

Wajsman

Klimberg

1989

Seminars in Surgical Oncology

View full text Add to dashboard Cite

Radical cystectomy remains the gold standard in the treatment of patients with muscle invasive bladder cancer. However, the specter of high failure rates coupled with morbid treatment methods has caused urologists, oncologists, and radiotherapists to explore modifications in, and alternatives to, the traditional treatments for invasive bladder cancer. The identification of the active methotrexate-platinum-based combination chemotherapy regimens heralds a new era in our ability to treat advanced disease effectively. Patients with less extensive muscle invasive tumors may be efficiaciously treated using conservative surgical excision, either alone or in combination with adjunctive treatments. In addition, definitive radiation therapy, given via the interstitial route or in combination with radiosensitizers, may result in long-term survival and preservation of bladder function. Progress has been made on multiple fronts in our ability to improve overall survival rates while allowing for the preservation of bladder function. The ability of these new mixed multimodality treatment initiatives to produce viable statistics equal to that of radical exenteration is an important landmark on the route towards an ideal treatment for invasive bladder cancer.

show abstract

Preoperative irradiation and cystectomy in 135 cases of bladder cancer

Cited by 63 publications

References 6 publications

Pelvic Lymphadenectomy and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder with Pelvic Nodal Disease

Pelvic Lymphadenectomy and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder with Pelvic Nodal Disease

Treatment of Infiltrating Bladder Cancer

Treatment alternatives for invasive bladder cancer

Contact Info

Product

Resources

About